{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:13:09Z","timestamp":1788235989210,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijgc.2025.101996","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:15:57Z","timestamp":1751379357000},"page":"101996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of PD-L1, tumor-infiltrating lymphocytes, and CD117 in vulvovaginal melanoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Chiau-Sheng","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-4649","authenticated-orcid":false,"given":"I-Chieh","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2025.101996_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.soc.2020.02.004","article-title":"Management of noncutaneous melanomas","volume":"29","author":"Lee","year":"2020","journal-title":"Surg Oncol Clin N Am"},{"issue":"20","key":"10.1016\/j.ijgc.2025.101996_bib2","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.3390\/cancers14205123","article-title":"Cutaneous Melanoma versus vulvovaginal Melanoma-Risk Factors, pathogenesis and Comparison of Immunotherapy Efficacy","volume":"14","author":"Lorenz","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101996_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.path.2021.01.005","article-title":"Mucosal melanoma: a review emphasizing the molecular landscape and implications for diagnosis and management","volume":"14","author":"Rawson","year":"2021","journal-title":"Surg Pathol Clin."},{"issue":"5","key":"10.1016\/j.ijgc.2025.101996_bib4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaad.2019.07.017","article-title":"Distinct genomic features in a retrospective cohort of mucosal, acral, and vulvovaginal melanomas","volume":"88","author":"Shi","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101996_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/ijgc-00009577-200109000-00004","article-title":"Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later","volume":"11","author":"Verschraegen","year":"2001","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101996_bib6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D\u2019Angelo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101996_bib7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/biomedicines9070758","article-title":"Vulvar and vaginal melanomas-the darker shades of gynecological cancers","volume":"9","author":"Dobric\u0103","year":"2021","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101996_bib8","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1097\/LGT.0000000000000204","article-title":"Surgical management and prognostic factors of vulvovaginal melanoma","volume":"20","author":"Ditto","year":"2016","journal-title":"J Low Genit Tract Dis"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101996_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/IGC.0000000000000013","article-title":"Primary malignant melanoma of the vagina: a retrospective clinicopathologic study of 44 cases","volume":"24","author":"Xia","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101996_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"7528","key":"10.1016\/j.ijgc.2025.101996_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.ijgc.2025.101996_bib12","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.ijgc.2025.101996_bib13","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1136\/ijgc-2024-005359","article-title":"The prognostic value of tumor-infiltrating lymphocytes in vulvovaginal melanoma","volume":"34","author":"Vanbockstael","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101996_bib14","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/cncr.30473","article-title":"Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma","volume":"123","author":"Hou","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101996_bib15","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 Phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10294","key":"10.1016\/j.ijgc.2025.101996_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101996_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1186\/s12885-021-08427-x","article-title":"Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract","volume":"21","author":"Cai","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101996_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CMR.0000000000000345","article-title":"Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma","volume":"27","author":"Hintzsche","year":"2017","journal-title":"Melanoma Res"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101996_bib19","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/bjd.15836","article-title":"KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas","volume":"177","author":"Dias-Santagata","year":"2017","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101996_bib20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/sj.bjc.6605635","article-title":"Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT","volume":"102","author":"Handolias","year":"2010","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101996_bib21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijgc.2025.101996_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920946158","article-title":"Successful treatment with avapritinib in patient with mucosal metastatic melanoma","volume":"12","author":"Cocorocchio","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101996_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.prp.2014.12.014","article-title":"DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma","volume":"211","author":"Zhao","year":"2015","journal-title":"Pathol Res Pract"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101996_bib24","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1309\/G6EK-Y6EH-0LGY-6D6P","article-title":"Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement","volume":"115","author":"Busam","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"10265","key":"10.1016\/j.ijgc.2025.101996_bib25","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101996_bib26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3892\/etm.2020.9510","article-title":"Immunohistochemical study of CD117 in various cutaneous melanocytic lesions","volume":"21","author":"Radu","year":"2021","journal-title":"Exp Ther Med"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101996_bib27","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1002\/1097-0142(19940515)73:10<2626::AID-CNCR2820731026>3.0.CO;2-U","article-title":"Malignant melanoma of the vulva treated by radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group","volume":"73","author":"Phillips","year":"1994","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101996_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2016.04.021","article-title":"Rare vulvar malignancies; incidence, treatment and survival in the Netherlands","volume":"142","author":"Pleunis","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101996_bib29","article-title":"Margin status in vulvovaginal melanoma: management and oncologic outcomes of 50 cases","volume":"49","author":"Straubhar","year":"2023","journal-title":"Gynecol Oncol Rep"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101996_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000441444","article-title":"Noncutaneous melanomas: a single-center analysis","volume":"232","author":"Del Prete","year":"2016","journal-title":"Dermatology (Basel"},{"key":"10.1016\/j.ijgc.2025.101996_bib31","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/PO.20.00150","article-title":"Meta-analysis of PD-L1 expression as a predictor of survival after checkpoint blockade","volume":"4","author":"Arf\u00e8","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ijgc.2025.101996_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104774","article-title":"Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG\/TRIM","volume":"96","author":"Placke","year":"2023","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101996_bib33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/LGT.0000000000000583","article-title":"Clinical characteristics and treatment response with checkpoint inhibitors in malignant melanoma of the vulva and vagina","volume":"25","author":"Wohlmuth","year":"2021","journal-title":"J Low Genit Tract Dis"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101996_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/cancers16010227","article-title":"Mucosal melanoma clinical management and prognostic implications: a retrospective cohort study","volume":"16","author":"Clavero-Rovira","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101996_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/CMR.0000000000000306","article-title":"Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma","volume":"27","author":"Shoushtari","year":"2017","journal-title":"Melanoma Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25011168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25011168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:13:57Z","timestamp":1788232437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25011168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1048891X25011168"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101996","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of PD-L1, tumor-infiltrating lymphocytes, and CD117 in vulvovaginal melanoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101996"}}